Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.

Maximilian Marhold,Lea Roxana Ionce,Alexandra Christ,Marie-Bernadette Aretin,Verena Sagaster,Ruth Exner,Kerstin Wimmer,Yelena Devyatko,Florian Fitzal,Guenther G. Steger

Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.

2019

Maximilian Marhold
Lea Roxana Ionce
Alexandra Christ
Marie-Bernadette Aretin
Verena Sagaster
Ruth Exner
Kerstin Wimmer
Yelena Devyatko
Florian Fitzal
Guenther G. Steger

e12114Background: Her2-positive (Her2pos) breast cancer (BCa) is the second most lethal subtype of BCa. The treatment of Her2-positive BCa was revolutionized due to the dual use of trastuzumab and ...

Keywords:

Trastuzumab
Breast cancer
Single Center
Pertuzumab
Pathology
HER2 Positive Breast Cancer
Oncology
Internal medicine
Medicine
outcome analysis
palliative treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations